TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01899794
Drug: Oxytrol
Normalized name: Oxytrol
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00007943
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01893099
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
Study: NCT02315976
Drug: Propatyl Nitrate
Normalized name: Propatyl nitrate
DrugBank: Propatyl nitrate (DB13255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propatyl nitrate 10mg administered orally, three times daily
Study: NCT03715829
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose 1. Oral tablet taken QD
Study: NCT03715829
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dose 2. Oral tablet taken QD
Study: NCT03715829
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose A. Oral tablet taken QD
Study: NCT03715829
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Dose B. Oral tablet taken QD
Study: NCT03715829
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Dose C. Oral tablet taken QD
Study: NCT01930708
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as per the approved dosage in all countries where DMF has received marketing authorization.
Study: NCT01176500
Drug: (18)Fluciclatide
Normalized name: Fluciclovine
DrugBank: Fluciclatide (DB14842)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00044395
Drug: Ruboxistaurin mesylate
Normalized name: mesylate
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020176
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020176
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03220256
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
Study: NCT00721110
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
Study: NCT00721110
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
Study: NCT00721110
Drug: Ketamine + Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: both Ketamine and Lidocaine will be given
Study: NCT00257010
Drug: Almotriptan Malate
Normalized name: Almotriptan Malate
DrugBank: Almotriptan (DB00918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
Study: NCT02624492
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02624492
Drug: GemOx
Normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02624492
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01538485
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly dose (based on 70IU KG body weight/day)
Study: NCT03321448
Drug: TMTP1-ICG
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of SLN
Study: NCT03321448
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of SLN
Study: NCT00364689
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00364689
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02562326
Drug: BioChaperone insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection immediately before the start of the individualised standard meal
Study: NCT00305942
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan 4mg/m2 IV on days 1, 8.
Study: NCT00305942
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC=5 IV day 1 only .
Study: NCT03154567
Drug: Yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
Study: NCT01681849
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Study: NCT02465112
Drug: In111-Pentetréotide
Normalized name: pentetreotide
DrugBank: Pentetreotide (DB12602)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163786
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
Study: NCT01950039
Drug: Betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine or placebo administered orally in divided doses over 12 weeks
Study: NCT04074837
Drug: NNI-362
Normalized name: NNI-351
DrugBank: NNI-351 (DB18048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNI-362 small molecule in liquid suspension.
Study: NCT00873886
Drug: Oseltamivir (Tamiflu)
Normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected.
Study: NCT03338920
Drug: sumatriptan nasal powder
Normalized name: sumatriptan Nasal Powder
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nasal powder administered via nosepiece
Study: NCT02274233
Drug: SP-420
Normalized name: SP-420
DrugBank: SP-420 (DB16069)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00087035
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
Study: NCT00087035
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be taken at a starting daily dose of 150mg
Study: NCT01586715
Drug: Adipose-derived stem cells without expanded
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study: NCT02839928
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
Study: NCT02839928
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04403685
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
Study: NCT02644057
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Study: NCT02644057
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Study: NCT01415687
Drug: Polyethylene Glycol-Based Lavage
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours.
Study: NCT01415687
Drug: Pico-Salax (Magnesium Citrate) plus Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre.
Study: NCT01942460
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03792074
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab Injection
Study: NCT03792074
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel Injection
Study: NCT03792074
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin injection
Study: NCT00003680
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003680
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00049946
Drug: talnetant
Normalized name: Talnetant
DrugBank: Talnetant (DB06429)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00049946
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00660231
Drug: bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
Study: NCT00660231
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
Study: NCT02825563
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the fasting state
Study: NCT02825563
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the high fat diet
Study: NCT02392169
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients used Retina or Concerta twice a day lasting for one year.
Study: NCT00003670
Drug: arzoxifene hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04057014
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic given at different dosages and durations.
Study: NCT00713154
Drug: MTS-01
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
Study: NCT03610022
Drug: Treatment with vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
Study: NCT04655976
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered.
Study: NCT04275518
Drug: APG-115
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-115 orally once daily from Days 1 to 7 every 28 days.
Study: NCT04275518
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
Study: NCT04275518
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Study: NCT03673072
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
Study: NCT03673072
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
Study: NCT02353598
Drug: Crenezumab dose level 1
Normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study: NCT02353598
Drug: Crenezumab dose level 2
Normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study: NCT02353598
Drug: Crenezumb dose level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Study: NCT03121547
Drug: Tapentadol 50 mg Oral Tablet
Normalized name: tapentadol 50 MG Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet administered
Study: NCT03121547
Drug: Tramadol Hydrochloride 100 mg Extended Release Oral Tablet
Normalized name: tramadol hydrochloride 100 MG Extended Release Oral Tablet
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet administered
Study: NCT01979484
Drug: PPI-668 capsule
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01979484
Drug: PPI-668 tablet
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02298946
Drug: AMP-224
Normalized name: AMP-224
DrugBank: AMP-224 (DB15767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg on day 1 then every 14 days for a total of 6 doses.
Study: NCT02262325
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02262325
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00423865
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
Study: NCT00423865
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
Study: NCT03555994
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide administered subcutaneously
Study: NCT03110510
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m2
Study: NCT00755287
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: starting dose 10 IU daily
Study: NCT00755287
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As prescribed
Study: NCT00755287
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once weekly
Study: NCT00755287
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
Study: NCT05076474
Drug: Orlistat 60mg Cap
Normalized name: ORLISTAT 60MG CAP
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
Study: NCT00009542
Drug: kava (Piper methysticum)
Normalized name: KAVA
DrugBank: Kava (DB01322)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02412436
Drug: Depot medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Depot medroxyprogesterone acetate intramuscular injection
Study: NCT01887197
Drug: mannitol inhalation powder
Normalized name: mannitol Inhalation Powder
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mannitol inhalation powder
Study: NCT00611286
Drug: clopidogrel treatment after bare metal stent implantation
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
Study: NCT00611286
Drug: clopidogrel treatment after bare metal stent implantation
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
Study: NCT00611286
Drug: clopidogrel after zotarolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
Study: NCT00611286
Drug: clopidogrel after paclitaxel-eluting stent implantation
Normalized name: Paclitaxel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
Study: NCT00611286
Drug: clopidogrel after everolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
Study: NCT00611286
Drug: clopidogrel after zotarolimus-eluting stent implantation
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.